According to China Intellectual Property Office's website, the patients in the country are demanding for compulsory licensing for allowing the domestic companies to manufacture the medicine 'Lamivudine' and market it at a lower price. The drug is used to treat Hepatitis B and HIV. The reason behind such demand is due to the less supply of Lamivudine during the second half of 2007. At present Pharma major GlaxoSmithKline (GSK) owns the Patent and marketing rights for Lamivudine in China.
ITAG Business Solutions Ltd. would not be held responsible for any opinion generated from views expressed in the article. The article are of personal use of technical experts and not necessary use of the organisation.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.